NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Endogena Therapeutics

Endogena Therapeutics

Private
ZurichHealthcare & Life Scienceshttps://endogena.com/

Last Round

Series A

Extension

Dec 13, 2021

Total Funding Raised

$29M

Company Overview

Endogena Therapeutics is a clinical-stage biotech company that discovers and develops first-in-class endogenous regenerative medicines to repair and regenerate tissues and organs, with a focus on degenerative diseases of the eye.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Medical AI, Precision Medicine

Business Model

B2B2C

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

regenerative medicineRetinitis PigmentosaRPstem cell therapysmall molecule therapeuticsendogenous stem cell activationgene-independent therapyretinal disease treatmentGeographic Atrophyvision restorationAge-related Macular DegenerationAMDphotoreceptor regenerationtissue regenerationclinical-stage biotechnologyOrphan Drug DesignationAI drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Endogena Therapeutics Comparables

Compare Endogena Therapeutics with similar companies based on industry and business-model similarity.

Endogena Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Endogena Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionDec 13, 2021
Series AJan 26, 2021
View all Funding Rounds

Endogena Therapeutics Investors

Notable investors and investment history

Endogena Therapeutics investors
InvestorRounds
DEFTA PartnersSeries A Extension, Series A
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 7, 2025

    Monthly visitors increased 41% MoM.

  • Dec 13, 2021

    $21M round led by Centenara Labs.

View all signals

Endogena Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Endogena Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Endogena Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersZurich
Employee Range3
Year Founded2016
Last FundingDec 13, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.